Vitamin D linked to MS progression
Researchers from the Harvard School of Public Health measured serum concentrations of 25-hydroxyvitamin D among a total of 465 participants in 18 European countries as well as Israel and Canada who were taking part in a clinical trial originally designed to look at the impact of early versus delayed interferon beta-1b treatment in those with a first event suggestive of MS.
The researchers found that higher levels of vitamin D in the first 12 months following this first event predicted slower progression of MS and reduced MS activity.
The findings suggest supplements could be a simple treatment for newly diagnosed patients.
Vitamin D levels were measured at onset of symptoms and again at six, 12 and 24 months to account for seasonal differences and to minimise the possibility that lower vitamin D levels were a consequence rather than a cause of MS progression.
Patients were followed up for five years for clinical